SG11201907927SA - Binding molecules that specifically bind to tau - Google Patents
Binding molecules that specifically bind to tauInfo
- Publication number
- SG11201907927SA SG11201907927SA SG11201907927SA SG11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA SG 11201907927S A SG11201907927S A SG 11201907927SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- archimedesweg
- leiden
- binding molecules
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163425 | 2017-03-28 | ||
PCT/EP2018/057770 WO2018178077A1 (en) | 2017-03-28 | 2018-03-27 | Binding molecules that specifically bind to tau |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907927SA true SG11201907927SA (en) | 2019-10-30 |
Family
ID=58448491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907927S SG11201907927SA (en) | 2017-03-28 | 2018-03-27 | Binding molecules that specifically bind to tau |
Country Status (10)
Country | Link |
---|---|
US (1) | US11028157B2 (de) |
EP (1) | EP3601335A1 (de) |
JP (1) | JP7109467B2 (de) |
KR (1) | KR20190133191A (de) |
CN (1) | CN110418804A (de) |
AU (1) | AU2018241857A1 (de) |
CA (1) | CA3056517A1 (de) |
EA (1) | EA201992281A1 (de) |
SG (1) | SG11201907927SA (de) |
WO (1) | WO2018178077A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
PE20200695A1 (es) | 2017-05-02 | 2020-06-16 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
GB201909393D0 (en) * | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1161548E (pt) | 1999-04-15 | 2005-06-30 | Crucell Holland Bv | Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus |
WO2012049570A1 (en) * | 2010-10-11 | 2012-04-19 | Panima Pharmaceuticals Ag | Human anti-tau antibodies |
WO2012149365A2 (en) | 2011-04-27 | 2012-11-01 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
DK2758433T3 (en) | 2011-09-19 | 2018-01-15 | Axon Neuroscience Se | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE |
ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
WO2015197823A2 (en) * | 2014-06-26 | 2015-12-30 | Crucell Holland B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
SG11201703237VA (en) | 2014-11-19 | 2017-06-29 | Axon Neuroscience Se | Humanized tau antibodies in alzheimer's disease |
-
2018
- 2018-03-27 EP EP18715587.4A patent/EP3601335A1/de not_active Withdrawn
- 2018-03-27 SG SG11201907927S patent/SG11201907927SA/en unknown
- 2018-03-27 US US16/497,916 patent/US11028157B2/en active Active
- 2018-03-27 WO PCT/EP2018/057770 patent/WO2018178077A1/en unknown
- 2018-03-27 AU AU2018241857A patent/AU2018241857A1/en not_active Abandoned
- 2018-03-27 KR KR1020197030544A patent/KR20190133191A/ko unknown
- 2018-03-27 CA CA3056517A patent/CA3056517A1/en active Pending
- 2018-03-27 JP JP2019552923A patent/JP7109467B2/ja active Active
- 2018-03-27 CN CN201880015336.1A patent/CN110418804A/zh active Pending
- 2018-03-27 EA EA201992281A patent/EA201992281A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
US11028157B2 (en) | 2021-06-08 |
EP3601335A1 (de) | 2020-02-05 |
US20210122810A1 (en) | 2021-04-29 |
KR20190133191A (ko) | 2019-12-02 |
EA201992281A1 (ru) | 2020-02-13 |
CA3056517A1 (en) | 2018-10-04 |
CN110418804A (zh) | 2019-11-05 |
JP2020511976A (ja) | 2020-04-23 |
JP7109467B2 (ja) | 2022-07-29 |
WO2018178077A1 (en) | 2018-10-04 |
AU2018241857A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201810801QA (en) | Brain delivery protein | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof |